FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The milestone of operating continuously a very complex system for over two years has demonstrated the effectiveness of integrated laboratory automation solutions
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Subscribe To Our Newsletter & Stay Updated
